NLRP3 and atrial fibrillation: Moreover, the results showed that preconditioning cardiomyocyte-specific knockdown of NLRP3 in mice confers protection against AF development, indicating that inhibition of NLRP3 could be a novel therapeutic strategy in AF (81).